Sciencast Management LP Lowers Holdings in CME Group (NASDAQ:CME)

Sciencast Management LP decreased its stake in shares of CME Group (NASDAQ:CME) by 38.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,516 shares of the financial services provider’s stock after selling 1,586 shares during the period. Sciencast Management LP’s holdings in CME Group were worth $390,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Capital International Investors boosted its stake in shares of CME Group by 11.4% during the 3rd quarter. Capital International Investors now owns 12,489,045 shares of the financial services provider’s stock valued at $1,694,514,000 after purchasing an additional 1,279,058 shares in the last quarter. Thornburg Investment Management Inc. boosted its stake in CME Group by 5.4% during the third quarter. Thornburg Investment Management Inc. now owns 3,902,886 shares of the financial services provider’s stock worth $529,544,000 after acquiring an additional 200,483 shares in the last quarter. Geode Capital Management LLC boosted its stake in CME Group by 5.4% during the fourth quarter. Geode Capital Management LLC now owns 3,695,039 shares of the financial services provider’s stock worth $538,556,000 after acquiring an additional 189,971 shares in the last quarter. Jackson Square Partners LLC boosted its stake in CME Group by 672.4% during the fourth quarter. Jackson Square Partners LLC now owns 2,773,705 shares of the financial services provider’s stock worth $405,099,000 after acquiring an additional 2,414,593 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in CME Group by 53.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,201,333 shares of the financial services provider’s stock worth $321,505,000 after acquiring an additional 764,129 shares in the last quarter. 83.11% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

In other CME Group news, insider Derek Sammann sold 2,400 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $161.66, for a total transaction of $387,984.00. Following the completion of the sale, the insider now directly owns 40,153 shares of the company’s stock, valued at $6,491,133.98. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ronald A. Pankau sold 200 shares of the company’s stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $159.91, for a total transaction of $31,982.00. Following the sale, the director now directly owns 3,809 shares of the company’s stock, valued at $609,097.19. The disclosure for this sale can be found here. Insiders have sold 40,699 shares of company stock valued at $6,266,062 over the last three months. 0.57% of the stock is owned by corporate insiders.

CME has been the topic of several research reports. Bank of America boosted their price objective on shares of CME Group from $175.00 to $185.00 and gave the stock a “buy” rating in a research note on Thursday, March 8th. Zacks Investment Research lowered shares of CME Group from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. BidaskClub raised shares of CME Group from a “hold” rating to a “buy” rating in a research note on Tuesday, January 9th. Berenberg Bank assumed coverage on shares of CME Group in a research note on Thursday, January 25th. They set a “hold” rating and a $170.00 price objective on the stock. Finally, Goldman Sachs upgraded shares of CME Group from a “neutral” rating to a “buy” rating and set a $180.00 target price on the stock in a research note on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $163.69.

Shares of CME traded down $4.73 during mid-day trading on Friday, hitting $158.26. 1,313,788 shares of the company traded hands, compared to its average volume of 2,112,036. The company has a quick ratio of 1.03, a current ratio of 1.03 and a debt-to-equity ratio of 0.10. CME Group has a 1 year low of $114.82 and a 1 year high of $171.71. The stock has a market capitalization of $53,869.33, a price-to-earnings ratio of 33.18, a PEG ratio of 2.19 and a beta of 0.56.

CME Group (NASDAQ:CME) last released its quarterly earnings data on Thursday, February 1st. The financial services provider reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.02. CME Group had a net margin of 111.49% and a return on equity of 7.68%. The firm had revenue of $900.00 million during the quarter, compared to analysts’ expectations of $886.85 million. During the same period in the previous year, the company earned $1.14 earnings per share. The firm’s quarterly revenue was down 1.4% on a year-over-year basis. analysts expect that CME Group will post 6.89 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 26th. Stockholders of record on Friday, March 9th were issued a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 1.77%. This is a boost from CME Group’s previous quarterly dividend of $0.66. The ex-dividend date was Thursday, March 8th. CME Group’s payout ratio is presently 58.70%.

WARNING: This piece of content was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/cme-group-inc-cme-position-cut-by-sciencast-management-lp.html.

About CME Group

CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products, and metals.

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply